HAIKOU, China, May 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a leading fully-integrated specialty pharmaceutical company in China, today announced that the Company's Chief Financial Officer, Mr. Frank Waung, has been invited to present at Piper Jaffray's Eighth Annual China Growth Conference in New York City on May 17, 2011. Conference details are as follows: Conference:
Piper Jaffray Eighth Annual China Growth Conference Date:
Tuesday, May 17, 2011Presentation time:3:30 p.m. ETLocation:
Le Parker Meridien118 West 57th StreetNew York, NY, 10019Mr. Waung will be available to meet with investors throughout the conference. Please contact your respective institutional sales representative for further details.
About China Pharma Holdings, Inc.China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across 30 provinces, municipalities and autonomous regions. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com .
Contact:China Pharma Holdings, Inc.
CCG Investor RelationsPhone: +86-898-6681-1730 (China)
Kalle Ahl, CFA, Account ManagerEmail: email@example.comPhone: (646) 833-3417 (New York)Email: firstname.lastname@example.orgVivian Chen, Sr. Market Intelligence Exec.Phone: (646) 701-7445 (New York)Email: email@example.com
|SOURCE China Pharma Holdings, Inc.|
Copyright©2010 PR Newswire.
All rights reserved